A federal judge in Manhattan has refused to hit pause on Johnson & Johnson's marketing for its prostate-cancer drug Erleada, rejecting Bayer's push to immediately stop ads that claim the medicine sharply cuts the risk of death compared with Bayer's rival treatment Nubeqa. For now, J&J's promotional campaign stays in place while Bayer's false-advertising case works its way through federal court.
Judge declines injunction
U.S. District Judge Dale Ho on Friday denied Bayer's request for an emergency injunction that would have forced J&J to dial back its claims. The court found that Bayer had not met the stringent standard required for such fast-track relief, according to Reuters.
What Bayer alleges
In its complaint, Bayer targets a Feb. 2 Johnson & Johnson press release and slide deck that leaned on a retrospective "real-world" head-to-head analysis comparing Erleada to Nubeqa. That analysis, J&J said, showed a 51% reduction in the risk of death for patients on Erleada versus those treated with Nubeqa.
Bayer's lawsuit describes the analysis as methodologically flawed and argues that J&J's promotional materials turn those findings into misleading superiority claims. The company is asking the court for a permanent injunction to stop the contested messaging, corrective notices, and damages under the Lanham Act, according to the filing posted by STAT.
J&J stands by its analysis
Johnson & Johnson, for its part, is not backing away from the data or how it was presented. The company has said it stands by both the methods and conclusions of the retrospective analysis and has defended its decision to spotlight the results in promotional materials.
In a statement reported by FiercePharma, J&J said it "stands by the rigor and integrity" of the work and added that "litigation does not change data."
Legal angle
At the heart of the dispute is a familiar but high-stakes question in pharmaceutical marketing: when does aggressive comparative advertising cross the line into false or misleading claims that illegally undercut a competitor?
Simpson Thacher, which filed the suit on Bayer's behalf, said the motion for a preliminary injunction was aimed at stopping what it characterizes as misleading superiority claims while the broader case plays out, according to Simpson Thacher.
Market stakes and next steps
Erleada is a multibillion-dollar oncology product for Johnson & Johnson, and Nubeqa is a key launch for Bayer, so every nuance in how doctors perceive the drugs can carry serious commercial weight. The advertising battle is fundamentally about shaping prescribing decisions and, with them, market share.
With the preliminary injunction off the table, at least for now, Bayer will have to prove its Lanham Act claims at a hearing or trial if it wants corrective relief or damages. Court filings and reporting outline the procedural steps ahead, including the materials cited above, as the case moves beyond this early skirmish over emergency relief.
